0.7911
price down icon3.70%   -0.0304
after-market Dopo l'orario di chiusura: .81 0.0189 +2.39%
loading

Allarity Therapeutics Inc Borsa (ALLR) Ultime notizie

pulisher
Apr 04, 2025

Allarity Therapeutics Inc (ALLR) Is A Good Stock To Invest In - stocksregister.com

Apr 04, 2025
pulisher
Apr 03, 2025

Reviewing Allarity Therapeutics (NASDAQ:ALLR) & Bright Minds Biosciences (NASDAQ:DRUG) - Defense World

Apr 03, 2025
pulisher
Apr 01, 2025

US Stocks Likely To Open Mixed After Disappointing Q1 Performance: 'April Does Better After A Weak Q1,' Says Expert - Benzinga

Apr 01, 2025
pulisher
Apr 01, 2025

XPeng, Ultralife And 3 Stocks To Watch Heading Into Tuesday - Benzinga

Apr 01, 2025
pulisher
Mar 31, 2025

Allarity Therapeutics, Inc. SEC 10-K Report - TradingView

Mar 31, 2025
pulisher
Mar 31, 2025

Allarity Therapeutics Reports Full Year 2024 Financial Results and Provides a Business Update - GlobeNewswire

Mar 31, 2025
pulisher
Mar 31, 2025

Allarity Therapeutics, Inc. (NASDAQ:ALLR) Short Interest Update - The AM Reporter

Mar 31, 2025
pulisher
Mar 26, 2025

Allarity Therapeutics (NASDAQ:ALLR) Trading 11% Higher – Still a Buy? - Defense World

Mar 26, 2025
pulisher
Mar 25, 2025

ALLR Shareholders are Encouraged to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm - PR Newswire

Mar 25, 2025
pulisher
Mar 25, 2025

Allarity Therapeutics probes potential stock manipulation By Investing.com - Investing.com Australia

Mar 25, 2025
pulisher
Mar 24, 2025

Allarity Therapeutics probes potential stock manipulation - Investing.com

Mar 24, 2025
pulisher
Mar 24, 2025

Allarity Therapeutics Launches Comprehensive Effort to Combat Potential Illegal Naked Short Selling of Its Shares - GlobeNewswire

Mar 24, 2025
pulisher
Mar 24, 2025

12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga

Mar 24, 2025
pulisher
Mar 24, 2025

Allarity Takes Bold Action Against Market Manipulation: Launches High-Tech Trading Investigation - Stock Titan

Mar 24, 2025
pulisher
Mar 19, 2025

Investigation announced for Long-Term Investors in shares - openPR.com

Mar 19, 2025
pulisher
Mar 19, 2025

ALLR Shareholders Are Encouraged To Join Allarity Therapeutics, Inc. Securities Fraud Investigation With The Schall Law Firm - MENAFN.COM

Mar 19, 2025
pulisher
Mar 17, 2025

Allarity Therapeutics Announces Presentation of Phase 2 - GlobeNewswire

Mar 17, 2025
pulisher
Mar 17, 2025

Allarity Therapeutics Presents Positive Phase 2 Data For Stenoparib In Advanced Ovarian Cancer - Nasdaq

Mar 17, 2025
pulisher
Mar 17, 2025

Allarity Therapeutics Announces Presentation of Phase 2 Clinical Data from Ongoing Trial in Advanced Ovarian Cancer Patients at the 2025 Annual Meeting for the Society of Gynecologic Oncology - The Manila Times

Mar 17, 2025
pulisher
Mar 17, 2025

Allarity reports promising ovarian cancer trial results - Investing.com

Mar 17, 2025
pulisher
Mar 17, 2025

Allarity Therapeutics Announces Presentation of Phase 2 Clinical Data from Ongoing Trial in ... - The Bakersfield Californian

Mar 17, 2025
pulisher
Mar 17, 2025

Breakthrough: New Cancer Drug Achieves 10-Month Complete Response in Advanced Ovarian Cancer Patients - StockTitan

Mar 17, 2025
pulisher
Mar 17, 2025

ALLR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Allarity Therapeutics, Inc. and Encourages Shareholders to Contact the Firm! - ACCESS Newswire

Mar 17, 2025
pulisher
Mar 14, 2025

ALLR Investors Have Opportunity to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm - PrimePublishers.com

Mar 14, 2025
pulisher
Mar 13, 2025

Allarity Therapeutics settles SEC investigation By Investing.com - Investing.com Australia

Mar 13, 2025
pulisher
Mar 13, 2025

SEC Says Allarity Leaders Hid FDA Issue Before Record Stock Drop - news.bloombergtax.com

Mar 13, 2025
pulisher
Mar 13, 2025

Allarity Therapeutics Announces Final Settlement with the U.S. Securities and Exchange Commission - GlobeNewswire

Mar 13, 2025
pulisher
Mar 13, 2025

Allarity Therapeutics Announces Final Settlement With The U.S. Securities And Exchange Commission - MarketScreener

Mar 13, 2025
pulisher
Mar 13, 2025

Allarity Therapeutics Reaches Final Settlement With SEC Over Past Disclosures -March 13, 2025 at 09:18 am EDT - Marketscreener.com

Mar 13, 2025
pulisher
Mar 13, 2025

Allarity Therapeutics Announces Final Settlement with SEC Over Previous Disclosures Regarding NDA for Dovitinib - Nasdaq

Mar 13, 2025
pulisher
Mar 13, 2025

Allarity Settles SEC Probe: $2.5M Fine Won't Impact Clinical Trials or 2026 Outlook - StockTitan

Mar 13, 2025
pulisher
Mar 12, 2025

SEC Says Ex-Allarity Execs Concealed Doomed FDA Approval - Law360

Mar 12, 2025
pulisher
Mar 10, 2025

ReShape Lifesciences, Allarity, Exact Sciences, CVS, AbbVie: 5 Health Care Stocks That Led Retail Message Grow - Asianet Newsable

Mar 10, 2025
pulisher
Mar 10, 2025

ReShape Lifesciences, Allarity, Exact Sciences, CVS, AbbVie: 5 Health Care Stocks That Led Retail Message Growth Last Week - MSN

Mar 10, 2025
pulisher
Mar 06, 2025

Allarity Therapeutics Announces Phase 2 Trial of Stenoparib - GlobeNewswire

Mar 06, 2025
pulisher
Mar 06, 2025

Allarity Therapeutics Announces Phase 2 Trial of Stenoparib and Temozolomide for Recurrent Small Cell Lung Cancer - Nasdaq

Mar 06, 2025
pulisher
Mar 06, 2025

Allarity Therapeutics Announces Phase 2 Trial of Stenoparib in Combination with Temozolomide for Recurrent Small Cell Lung Cancer Fully Funded by the US Veterans Administration - The Manila Times

Mar 06, 2025
pulisher
Mar 06, 2025

Can This Dual-Action Cancer Drug Overcome Previous PARP Inhibitor Limitations? - StockTitan

Mar 06, 2025
pulisher
Mar 05, 2025

Allarity Therapeutics, Inc. (NASDAQ:ALLR) Short Interest Up 30.0% in February - Defense World

Mar 05, 2025
pulisher
Mar 04, 2025

BDSX Shrinks Loss With Revenue Growth, ALLR Plans $5Mln Share Buyback, What's The Buzz At PTIX? - RTTNews

Mar 04, 2025
pulisher
Mar 04, 2025

Allarity Therapeutics (NASDAQ:ALLR) Board Authorizes Share Buyback Program - Defense World

Mar 04, 2025
pulisher
Mar 03, 2025

Allarity Therapeutics Announces Board Authorization Of $5 Million Share Repurchase Program - TradingView

Mar 03, 2025
pulisher
Mar 03, 2025

Allarity Therapeutics Announces Board Authorization of $5 Million Share Repurchase Program - GlobeNewswire

Mar 03, 2025
pulisher
Mar 03, 2025

Can Allarity's $5M Share Repurchase Signal Hidden Value in Its Cancer Treatment Pipeline? - StockTitan

Mar 03, 2025
pulisher
Mar 03, 2025

Allarity Board Authorizes Share Repurchase Program - Nasdaq

Mar 03, 2025
pulisher
Feb 27, 2025

ALLR STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Allarity Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Feb 27, 2025
pulisher
Feb 26, 2025

Allarity Therapeutics Announces Dismissal of Securities Class Action Lawsuit - GlobeNewswire

Feb 26, 2025
pulisher
Feb 26, 2025

Legal Victory: How Allarity Therapeutics Defeated Its Securities Class Action Without Paying a Dime - StockTitan

Feb 26, 2025
pulisher
Feb 24, 2025

Allarity Therapeutics stock hits 52-week low at $0.87 By Investing.com - Investing.com Nigeria

Feb 24, 2025
pulisher
Feb 24, 2025

Allarity Therapeutics stock hits 52-week low at $0.87 - Investing.com

Feb 24, 2025
pulisher
Feb 24, 2025

Allarity Therapeutics to Begin Enrollment for New Phase 2 - GlobeNewswire

Feb 24, 2025
pulisher
Feb 24, 2025

Can This New Ovarian Cancer Drug Challenge the $9B PARP Market? Complete Response Data Emerges - StockTitan

Feb 24, 2025
$60.58
price down icon 3.01%
$69.18
price down icon 5.66%
$17.36
price down icon 8.20%
$31.11
price down icon 2.14%
$88.05
price down icon 4.30%
biotechnology ONC
$238.51
price down icon 9.76%
Capitalizzazione:     |  Volume (24 ore):